An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

Inclusion Criteria: * Histologically confirmed Stage 4 or recurrent non-small cell lung cancer * Eastern Cooperative Oncology Group (ECOG) score 0-1 (Physically able to carry out light housework or office work through to being fully active as you were before cancer) * No prior systemic anticancer therapy (including EGFR and ALK inhibitors) * Tissue or Programmed death-ligand 1 (PD-L1) results available Cohort 1A Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) score 2 or * Eastern Cooperative Oncology Group (ECOG) score 0-1 and one disease specific criteria as listed in the protocol Cohort C Inclusion Criteria: * High Tumor Mutation Burden Exclusion Criteria: * Untreated brain metastases * An active malignancy that requires concurrent intervention * Active, known or suspected autoimmune disease * Carcinomatous meningitis, which means there is inflammation of the covering of the brain, caused by cancer Other protocol-defined inclusion/exclusion criteria apply